• About us
• Contact

Advertisement

Organisation › Details

Domain Therapeutics (Group)

Domain Therapeutics is a biopharmaceutical company based in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G protein -coupled receptors (GPCRs), one of the most important classes of drug targets. Domain Therapeutics identifies and develops new drug candidates, allosteric modulators and biased ligands through its innovative approach and distinctive technologies. The company provides access to its technologies through research and collaborative agreements. It develops its own pipeline for components up to the stage of optimized lead product for major indications in central nervous system and metabolic disorders. In January 2014, the company established its subsidiary, Domain Therapeutics NA Inc., at the NEOMED Institute in Montreal, Canada. *

 

	Start	2008-12-01 renamed
	Predecessor	Faust Pharmaceuticals S.A.
	Industry	GPCR inhibitor
	Industry 2	CNS drug (neurological drug)
	Person	Neuville, Pascal (Domain Therapeutics 200812c– CEO)
	Person 2	Malmezat, Stanislas-Léonard (Domain Therapeutics 202205 CFO)
	Region	Illkirch
	Country	France
	Street	850 Boulevard Sébastien Brant Bioparc
	City	67400 Illkirch
	Tel	+33-3-9040-6150
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Domain Therapeutics (Group)

• [1] Domain Therapeutics S.A.. (5/12/22). "Press Release: Domain Therapeutics Raises $42m Series A Financing to Accelerate Clinical Development of Its Best-in-Class and First-in-Class Immuno-oncology Programs". Strasbourg & Montréal, ON....
• [2] Domain Therapeutics S.A.. (1/13/20). "Press Release: Domain Therapeutics Secures €6 Million ($6.7M) Debt Financing". Strasbourg....
• [3] Domain Therapeutics S.A.. (9/11/19). "Press Release: Domain Therapeutics Invests in Ermium Therapeutics to Develop First-in-class CXCR4 Candidate for Autoimmune Diseases". Strasbourg....
• [4] Domain Therapeutics S.A.. (5/28/19). "Press Release: European Venture Capital Firm Seventure Partners Renews Its Support to Domain Therapeutics and Invests €3.5M ($3.9M) to Prepare the Next Growth Phase". Strasbourg....
• [5] Domain Therapeutics S.A.. (12/4/18). "Press Release: Domain Therapeutics Signs a Multi-target Research Collaboration and License Agreement with Boehringer Ingelheim on G Protein-Coupled Receptors (GPCRs) for Central Nervous System Disorders". Strasbour...
• [6] Domain Therapeutics S.A.. (4/25/17). "Press Release: Pfizer Inc. and Domain Therapeutics Enter into a Collaboration Agreement on bioSensAll". Strasbourg & Montréal, ON....
• [7] Merck KGaA. (1/23/17). "Press Release: Merck Announces Research Collaboration with Domain Therapeutics in Immuno-Oncology [Not intended for UK- or US-based media]". Darmstadt....
• [8] Domain Therapeutics S.A.. (1/23/17). "Press Release: Domain Therapeutics and Merck Enter into a License and Collaboration Agreement for Development of Adenosine Receptor Antagonists in Immuno-oncology". Strasbourg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.